艾伯维(ABBV.US)斥资12亿美元收购Gilgamesh旗下实验性抗抑郁治疗药物

智通财经
Aug 26
【艾伯维(ABBV.US)斥资12亿美元收购Gilgamesh旗下实验性抗抑郁治疗药物】智通财经APP获悉,艾伯维(ABBV.US)同意以高达12亿美元的价格收购Gilgamesh Pharmaceuticals旗下一款实验性抗抑郁治疗药物。根据协议条款,艾伯维将收购Gilgamesh的核心候选药物bretisilocin,该药物正在开发用于治疗重度抑郁症。与此同时,Gilgamesh将把其其他研发项目剥离,组建一家新的实体公司—— Gilgamesh Pharma Inc.。双方表示,这笔交易仍需满足惯例的交割条件。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10